PUNE, India, November 1, 2016 /PRNewswire/ -- ReportsnReports.com adds "Lupus Nephritis - Pipeline Review, H2 2016" to its store providing comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lupus Nephritis and features dormant and discontinued projects. Complete report on Lupus Nephritis Market Research with 37 market data tables and 15 figures, spread across 142 pages is available at http://www.reportsnreports.com/reports/729119-lupus-nephritis-pipeline-review-h2-2016.html . Companies discussed in this research report include AbbVie Inc, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Aurinia Pharmaceuticals Inc, Azano Pharmaceuticals Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Deltanoid Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, HanAll Biopharma Co., Ltd., Invion Limited, KPI Therapeutics, Inc., MedImmune, LLC, Omeros Corporation, Ra Pharmaceuticals, Inc., Resolve Therapeutics, LLC, Takeda Pharmaceutical Company Limited and TxCell SA. Drug Profiles mentioned in this research are abatacept, anifrolumab, belimumab, BI-655064, BMS-986147, dalazatide, DP-001, Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis, ENTX-DN, HL-161, INV-103, ixazomib citrate, mizoribine, Monoclonal Antibody for Lupus Nephritis, obinutuzumab, OMS-721, P-Dex, RA-101495, RO-5461111, RSLV-145, Stem Cell Therapy for Autoimmune Diseases, Synthetic Peptide to Inhibit Complement C5 for Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome and Autoimmune Disorders, venetoclax, voclosporin and Y-175L. Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE). Also called lupus, SLE is an autoimmune disease. Symptoms include weight gain, high blood pressure, dark urine and foamy, frothy urine. Treatment includes corticosteroids, immunosuppressive drugs and health lifestyle. Lupus Nephritis pipeline therapeutics constitutes close to 25 molecules. Out of which approximately 22 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 4, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.